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Silymarin content in Silybum marianum extracts as a biomarker for the quality 
of commercial tinctures 
 
Abstract 
Silybum marianum (L.) Gaertner (Milk thistle) extracts have been widely used for the 
treatment of liver pathologies and as a hepatoprotectant against alcohol-induced liver 
diseases and other harmful drug metabolites or toxins. Silymarin, the active fraction 
of Silybum marianum tinctures, accounts for 70-80% of the plants hydro-alcoholic 
extract and consists of a mixture of flavonolignans and a flavonoid. Silybum 
marianum tinctures are commonly prescribed by herbal practitioners for the treatment 
of liver diseases. However, previous studies have showed inconsistency in the 
therapeutic efficacy of Silybum marianum tinctures, which is believed to have arisen 
from the content variability of silymarin, resulting from lack of standardized and 
regulated manufacturing processes. This work was conducted to quantify the 
silymarin content in commercial Silybum marianum tinctures in order to evaluate their 
quality. In this study, we report the determination of the total silymarin content in 
eleven different commercial tinctures produced in the U.K. using a convenient and 
accurate HPLC-UV method. The tinctures analyzed differed in the ratio between herb 
and liquid as well as percentage of ethanol used during the extraction process. Our 
results showed a direct correlation between the silymarin content in tinctures and the 
alcohol strength. Following our protocol, silymarin could not be detected in tinctures 
extracted with 25% ethanol. Effective therapeutic doses were found only in tinctures 
with a concentration ratio herb to liquid 1:1 (kg/L) and an alcoholic content of 70%. 
To guarantee quality and safety of herbal medicinal products, legal requirements to 
produce plant-based products under regulatory frameworks are needed. 
Key words: Silymarin, Silybum marianum, HPLC, alcoholic extracts, quality control, 
biomarker 
 
1. Introduction 
 
Silybum marianum (L.) Gaertner (milk thistle) is a spiny annual or biennial plant, 
native to the Mediterranean but found growing throughout Europe. Traditionally the 
plant extract has been used for a variety of acute and chronic liver diseases. The 
crude hydro-alcoholic extract of crushed seeds (achene, Fructus silybi) that develop 
from the plant’s purple flowers contains from 65% to 80% of silymarin, whereas the 
remaining 35% to 20% accounts for uncharacterized polyphenols and fatty acids, 
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including linoleic, oleic and palmitic acids. Silymarin is widely considered to be the 
principal active fraction in milk thistle tinctures, and is known to be primarily a mixture 
of a variety of flavonolignans and the flavonoid taxifolin. The main flavonolignans 
identified in silymarin are reported in Fig. 1.  
Clinical trials using silymarin preparations have provided support for its traditional 
use as a hepatoprotective agent, showing both a protective and curative effect in the 
treatment of acute and chronic hepatitis, alcohol-related liver diseases and liver 
damage resulting from highly toxic compounds, including from the death cap 
mushroom Amanita phalloides (Blumenthal, 2000; Fraschini et al., 2002). In vitro 
anti-inflammatory, anti-arthritic, antioxidant and anti-carcinogenic properties have 
also been documented (Gupta et al., 2000; Pendry et al., 2006; Shaker et al., 2010; 
Zhao et al., 2011; Agarwal et al., 2013) as well as clinical trials testing silymarin in 
cancer therapy (Invernizzi et al., 1993; Schrӧder, F.H. et al., 2005; Greenlee, H. et 
al., 2007; Shahbazi, F. et al., 2015; Elyasi, S. et al., 2016). 
Tinctures are the most widely applied pharmaceutical form of plant medicine 
among herbal practitioners. Currently, tincture manufacturers are not legally required 
to regulate their products under any regulatory frameworks in order to assure quality 
and safety of botanicals. As a consequence, the majority of the herbal medicines and 
food supplements are still sold as unlicensed products. This causes difficulties for 
herbal practitioners and consumers to distinguish between high- and low-quality 
products, as well as unreliability in dosage and treatments outcomes.   
Previous studies have shown that silymarin content variability has led to 
inconsistent therapeutic efficacy of Silybum marianum (Saller et al., 2001; Rambaldi 
et al., 2005). According to Bone (2003), aqueous ethanol extracts of Silybum 
marianum should contain not less than 25 mg/mL silymarin, and a therapeutic dose 
of 4.5-8.5 mL of 1:1 liquid extract accounting for a total uptake of 113-213 mg/day of 
silymarin is recommended for the treatment of hepatitis and liver-associated 
diseases. This therapeutic guideline was further supported by clinical studies into the 
therapeutics benefits of silymarin, where a dose-response window of 200-400 mg per 
day was identified (Wichtl, 2004).  
The aim of this study was to quantify the silymarin content in commercial Silybum 
marianum tinctures in order to verify whether these products ensured both 
consistency of quality and dosage, and made treatment outcomes easier to evaluate. 
Eleven different Silybum marianum tinctures commercially available in the U.K. were 
tested using a convenient and accurate HPLC-UV analytical method. Ultimately, this 
study aims to provide herbal practitioners and consumers with a better understanding 
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of the quality of commercial tinctures as well as to help manufacturers gain and 
maintain their trustworthiness in the tinctures market. 
 
2. Materials and Methods  
 
Reference standard for silymarin (mixture of flavonolignans) purchased from 
Sigma-Aldrich (Steinheim, Germany) catalogue no. S0292.  Methanol (Assay (GC) of 
99.99%) and ethanol (99.7% - 100%) were HPLC grade (Fisher Scientific UK Ltd). 
Glacial acetic acid (min. 99.8%) was analytical grade (AnalaR® DBH Laboratories 
Supplies, Poole, England). Water was purified in the laboratory with an ELGA water 
purification system (model OPTION-S 15BP).  
The HPLC system was composed of a Perkin-Elmer Model Series 410 Liquid 
Chromatograph gradient pump (USA), a Hewlett Packard Series 1050 auto sampler 
(USA), and a Varian 2550 Variable λ UV detector (USA). The HPLC system was 
controlled, data integrated and evaluated by a Windows 98 PC operating Perkin 
Elmer TotalChrom software for chromatography, which communicated with the UV 
detector through a Perkin Elmer NC1900 Interface. The mobile phase was degassed 
prior to use with an ultrasonic bath by Kerry Ultrasonic Ltd.  
 
2.1. Tinctures 
Tinctures of Silybum marianum were purchased from eight manufacturers 
commonly used by herbal practitioners in the U.K. The samples, eleven in all, were 
randomly labelled A-K and their identity was not known until after the analyses were 
complete (Table 1). 
 
2.2. Standard and sample preparation  
A stock solution of silymarin was prepared in methanol at a concentration of 1 
mg/mL, and serial dilutions were made to obtain standard concentrations at the 
following concentrations: 0.65, 0.5, 0.25, 0.125, 0.02 mg/mL. Samples were stored at 
4C (storage time 3 months). Commercial tinctures were prepared by diluting 50 µL 
of the tincture with 950 µL of methanol and the resulting dilution centrifuged at 13000 
rpm for 5 min with an accuSpin™ Micro centrifuge (Fisher Scientific, UK). A volume 
of 200 µL of the supernatant was placed into HPLC vials and a 20 µL aliquot injected 
onto the HPLC column for each analysis. All analysis were made in triplicate. 
 
2.3. Chromatography conditions 
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Separations were achieved using a Luna 5µm C18 100R reversed phase column 
(Phenomenex® Ltd UK) of 150 X 4.60 mm i.d. The column was equipped with a 
Phenomenex SecurityGuard™ C18 cartridge (4 mm X 3.0 mm i.d). The flow rate was 
1 mL/min using a gradient mobile phase of 2% acetic acid (A) and methanol 
/water/acetic acid (18:1:1 % v/v) (B). The starting mobile phase was 75:25 A:B 
increased to 100% B in a linear gradient over 20 min, held for 4 min and returned in 1 
min to 75:25 for the next injection. UV detection of calibration and tincture samples 
were monitored at 285 nm and data processed by Totalchrom software. 
 
3. Results  
 
3.1. Validation procedure 
A set of six standard solutions of silymarin was prepared in methanol at concentrations 
ranging from 1 mg/mL to 0.02 mg/mL. Figure 2 represents the characteristic 
chromatographic profile of a standardized silymarin extract (Bilia et al., 2001; Lee et 
al., 2007; Liu et al., 2009), where a double cluster of peaks from 12-14 and 16-18 min 
is still identifiable at the lowest concentration of 0.02 mg/mL. Liu et al (2009) identified 
the 2 peaks of the first cluster as silychristin and isosilychristin plus silidianin, 
respectively, and the first 2 peaks of the second cluster as silybin A plus B with the 
remaining 2 major peaks as isosilybin A plus B. Although the peaks are unresolved to 
base line (as Quaglia et al 1999 found for some peaks), the calibration curve was 
constructed by plotting the sum of the peak area corresponding to the seven 
flavonolignans and taxifolin (tr = 9.33 min) against the concentration using a linear 
regression analysis (R2 = 0.99). Graf et al. (2016) investigated the potential matrix 
effect which is typical of natural product extracts by using and comparing HPLC-UV 
and LC-MS methods. The authors demonstrated that both detections were effective in 
quantifying silymarin extracts, and that matrix effect was negligible remarking that MS 
and UV are both valid techniques for the quantification of silymarin mixture. Since 
herbal practitioners prescribe therapeutic doses of Silybum marianum tincture based 
on silymarin content, herein we reported our results as the total content of silymarin 
expressed as mg/mL. The silymarin concentration (mg/mL) in tinctures was calculated 
using the sum of the peak area corresponding to the seven main flavonolignans and 
taxifolin.  
 
3.2. Limit of Detection and Limit of Quantitation 
The limit of detection (LOD) based on a signal-to-noise ratio (S/N: 3) was 0.08 
µg/mL. The limit of quantitation (LOQ) based on the signal-to-noise ratio (S/N: 10) 
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using the lowest concentration in the calibration curve and the highest noise 
observed when injecting a blank was 0.25 µg/mL (Rosing et al., 2000). For a 20 µL 
sample injection, these correspond to 1.6 ng (LOD) and 5.2 ng (LOQ). 
 
3.3. Accuracy and precision 
The intraday coefficient of variation (%CV) was calculated for the retention times 
and peak areas for all injections per sample (x 3). The %CV was deemed acceptable 
at < 5% for peak areas and < 1% for retention times. The analytical data shown for 
the commercial tinctures indicate the accuracy and confidence of the reported 
method (Rosing et al, 2000). 
 
3.4. Herbal Tinctures Formulations 
Silymarin content was determined in eleven commercial tincture products (A-K) 
produced by eight different manufactories in the U.K. (Table 1). Samples differed in 
the ratio between the dry herb weight and the solvent volume (kg/L) and in the 
percentage of ethanol used during the extraction process. Sample J, produced by 
using 70% of ethanol content during the extraction process, recorded the highest 
concentration of silymarin (18.37 ± 0.25 mg/mL). Whilst samples E, F and I (alcoholic 
percentage between 45 – 51%) showed a moderate silymarin content (4.75 ± 0.17 
mg/mL, 4.54 ± 0.35 mg/mL and 5.02 ± 0.11 mg/mL respectively), the amount of 
silymarin could not be quantified in all the remaining samples, which were extracted 
with 25% of alcohol. Figure 3 depicted the chromatographic profile of samples J and 
E, where all the characteristic silymarin peaks are distinguishable (Figure 3a and 3b, 
respectively), and sample D, where none of the typical cluster patterns can be 
identified (Figure 3c).    
 
 
4. Discussion  
 
This work was part of a quality control study on commercial tinctures of Silybum 
marianum, and reflects previous work in our laboratory demonstrating the extent of 
the variation in the biomarker content of commercially available herbal medicines 
(Sanchez-Medina et al., 2007; Gao et al., 2008). By developing a suitable HPLC-UV 
method, we demonstrated significant differences in chemical composition and 
variability among Silybum marianum tinctures. The results of silymarin analysis in the 
commercial tincture products show a clear pattern between silymarin concentration 
and alcohol strength with increasingly higher amounts detected as the ethanol ratio 
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increased (Table 1). These results appear to support the results of Bilia et al. (2001) 
who detected considerably lower flavonolignan levels in a 40% v/v Silybum 
marianum tincture compared with 60% v/v. According to Bone (2003), the suggested 
daily dose of a Silybum marianum tincture (70%, 1:1) is 4.5 – 8.5 mL containing not 
less than 25 mg/mL silymarin. Our data shows that of eleven commercial tincture 
products, only J could be reasonably administered following the recommended daily 
dose of 8 mL per day (Table 1); whereas for sample E, F and I, a daily dose of 150 
mg (median daily dose) silymarin would correspond to approximately 30 mL of 
tincture daily. Remarkably, all the tinctures extracted with 25% were far from 
satisfying this therapeutic guideline at any ratio between the dry herb weight and the 
solvent volume.  
The majority of trials investigating the therapeutic potential of Silybum marianum 
have been carried out using extracts standardized to contain at least 70% silymarin. 
Our data showed that the majority of the samples investigated had poor 
phytochemical quality as they were far from meeting this concentration. Despite their 
popularity as an herbal medicine, Silybum marianum tinctures may provide an 
unsuitable dosage of silymarin unless standardized to the recommended silymarin 
concentrations (mg/mL). To guarantee both consistency of quality and dosage, and 
make treatment outcomes easier to evaluate, a legal requirement for herbal 
medicinal producers to comply with a regulatory framework should be considered.  
 
 
5. Conclusion  
 
The current study aimed to determine the silymarin content in Silybum marianum 
tinctures produced by eight different retailers in the U.K. This HPLC method proved 
to be an invaluable tool for the analysis of silymarin in hydro-alcoholic extracts. The 
authors demonstrated that extraction processes of silymarin involving less than 45% 
of alcohol is unsuitable for therapeutic uses as the silymarin content was negligible. 
Low levels of silymarin were also detected in tinctures extracted with 45-50% 
ethanol. To ensure effective treatment outcomes, the use of tinctures with a 
concentration ratio herb to liquid 1:1 (kg/L) and an alcoholic content of 70% is 
strongly recommended.  
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Table 1.  
Silymarin content, expressed as mg/mL, in commercial tincture samples 
produced with different ethanol-water ratio extraction processes and the 
corresponding volume required to reach a suggested therapeutic dose of 150 
mg/day (median daily dose). 
Samplea % ethanol in 
waterb 
Silymarin  
(mg/mL ± SD) 
mL/day required for a 
therapeutic dosec 
A    (1:1) 25 ND - 
B    (1:5) 25 ND - 
C    (1:3) 25 ND - 
D    (1:1) 25 ND - 
E    (1:1.33) 51 4.75 ± 0.17 31.5 
F    (1:3) 45 4.54 ± 0.35 33.0 
G    (1:1) 25 ND - 
H    (1:3) 25 ND - 
I    (1:1) 45 5.02 ± 0.11 30.0 
J    (1:1) 70 18.37 ± 0.25 8.2 
K    (1:3) 25 ND - 
a In brackets concentration ratio herb to liquid (kg/L) and b percentage of ethanol used 
during the extraction process of the commercial tinctures. c Amount of tincture 
expresses as mL/day required to reach a therapeutic dose of 150 mg, extrapolated 
from the determined silymarin concentration (mg/mL). ND = not detected 
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Fig 1. Chemical structure of the flavonoid taxifolin and the seven main flavonolignans 
present in silymarin:  silybin A and B, isosilybin A and B (two diastereomeric pairs 
accounting for 50% of silymarin), silychristin, isosilychristin and silydianin. 
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